Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
5
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
5
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
boston top stories
cancer
cancer immunotherapy
deals
gilead sciences
abbvie
drug prices
ipo
medicare
aducanumab
What
bio
roundup
5
×
drug
acquisitions
ceo
companies
covid
ipo
medicines
new
price
activity
albert
alzheimer’s
announced
approval
approvals
biggest
biogen
biogen’s
biopharmaceutical
bourla
clamped
collabs
company
convo
crispr
daniel
deal
delays
developing
different
earlier
economic
fail
failures
fast
fda
future
gene
Language
unset
unknown
Current search:
roundup
×
novartis
×
startups
×
biogen
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More